Regeneron Pharmaceuticals, Inc.
MODIFIED DOSAGE OF SUBCUTANEOUS TOCILIZUMAB FOR RHEUMATOID ARTHRITIS
Last updated:
Abstract:
The present disclosure relates the dosage modification and choice of an IL6 antibody for the treatment of rheumatoid arthritis in subjects.
Status:
Application
Type:
Utility
Filling date:
11 Jun 2020
Issue date:
4 Aug 2022